Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Benzinga · 06/17/2024 12:43
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose sharply in today's pre-market trading after the company announced results from its ongoing clinical trial of NX-5948 in patients with relapsed refractory chronic lymphocytic leukemia.
Nurix Therapeutics shares jumped 12.1% to $17.01 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
Gainers
- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) rose 89.4% to $6.61 in pre-market trading after surging 24% on Friday. Scinai Immunotherapeutics, last week, received a non-binding Letter of Intent from the European Investment Bank for converting loan into equity.
- Interactive Strength Inc. (NASDAQ:TRNR) shares rose 76.6% to $5.05 in pre-market trading after dipping 19% on Friday.
- ENDRA Life Sciences Inc. (NASDAQ:NDRA) gained 36.4% to $0.1414 in pre-market trading after a 13G filing showed a 9.99% passive stake from S.H.N. Financial Investments Ltd.
- The Aaron’s Company, Inc. (NYSE:AAN) gained 32.1% to $9.96 in pre-market trading after the company announced that it entered into a definitive agreement to be acquired by IQVentures Holdings.
- Venus Concept Inc. (NASDAQ:VERO) gained 26.1% to $1.18 in pre-market trading after the company announced that it has entered a new strategic resurfacing and skin tightening device supply arrangement with Skin Laundry Holdings.
- SRIVARU Holding Limited (NASDAQ:SVMH) shares gained 16.4% to $0.2649 in pre-market trading. SRIVARU shares jumped 49% on Friday after the company announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16th.
- Kineta, Inc. (NASDAQ:KA) rose 15.4% to $0.5990 in pre-market trading after gaining around 10% on Friday.
- IceCure Medical Ltd (NASDAQ:ICCM) shares rose 14% to $0.93 in pre-market trading after gaining around 8% on Friday.
- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) shares climbed 13.4% to $2.37 in pre-market trading after falling around 5% on Friday. XTL recently entered into definitive agreement to acquire The Social Proxy.
Losers
- Ovid Therapeutics Inc. (NASDAQ:OVID) shares fell 64.1% to $1.18 in pre-market trading after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint
- Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) shares fell 33.2% to $3.98 in pre-market trading. Kaival Brands Innovations Group shares jumped 338% on Friday after the company announced a $5 million offering of 3,012,048 units at $1.66 per unit.
- iPower Inc. (NYSE:IPW) shares fell 28.7% to $2.35 in pre-market trading after the company announced a $5 million registered direct offering.
- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) fell 22% to $0.3980 in pre-market trading after jumping 12% on Friday.
- Feutune Light Acquisition Corporation (NASDAQ:FLFV) shares fell 17.8% to $8.06 in pre-market trading.
- BIMI Holdings Inc. (NASDAQ:BIMI) shares fell 15.6% to $1.86 in pre-market trading after gaining 23% on Friday.
- La Rosa Holdings Corp. (NASDAQ:LRHC) shares declined 12.8% to $1.02 in pre-market trading. La Rosa Holdings shares jumped around 76% on Friday after the company filed a request for the withdrawal of its registration statement on a Form S-1.
- Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) shares dipped 12% to $1.91 in pre-market trading after dipping over 10% on Friday.
- AMC Networks Inc. (NASDAQ:AMCX) fell 9.4% to $14.24 in pre-market trading after the company announced a private offering of $125 million of convertible senior notes.
- Evotec SE (NYSE:EVO) shares declined 7.7% to $4.20 in pre-market trading.
Now Read This: Investor Optimism Continues To Wane Despite Nasdaq’s Fifth Consecutive Record Close On Friday
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.